Treatment patterns, outcomes and testing in EGFRm NSCLC patients with EGFR TKI 1L across Europe (REFLECT) - REFLECT
Study identifier:D5162R00009
ClinicalTrials.gov identifier:NCT04031898
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Real World Treatment Patterns, Clinical Outcomes and EGFR / T790M Testing Practices in EGFR-Mutated Advanced Non–Small cell Lung Cancer Patients Receiving First-Line TKI Therapy
Medical condition
lung cancer
Phase
N/A
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
896
Study type
Observational
Age
N/A
Date
Study Start Date: 07 May 2019
Primary Completion Date: 31 Dec 2019
Study Completion Date: 31 Dec 2019
Study design
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Dec 2020 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| full analysis set All eligible patients who meet all inclusion criteria and none of the exclusion criteria | Other: Non Interventional This is a non interventional, observational, retrospective study including patients with EGFR-mutated advanced NSCLC, treated with 1st or 2nd generation EGFR TKI therapy in first line Other Name: NA |
Contacts
Investigators
Principal Investigator
Konstantinos Syrigos
Oncology Unit, Athens University School of Medicine,
